Verification of the interaction between peptide T and CD4 using surface plasmon resonance.
Peptide T is currently in phase II clinical trials for the treatment of AIDS-associated dementia. Its putative mode of action is inhibition of binding of the HIV envelope protein (gp120) to its cellular receptor (CD4), thus preventing viral infectivity and gp120-induced neuronal toxicity. However, a number of reports have appeared in the literature which have failed to observe any inhibitory activity of Peptide T on CD4-gp120 binding, thus casting doubt on this hypothesis. This study uses a novel biosensor technique to demonstrate that Peptide T does bind to CD4 and that this binding can be specifically inhibited by an anti-CD4 monoclonal antibody. A detailed analysis of the kinetics of the interaction is presented.
Ramsdale
T E
TE
Centre for Drug Design and Development, University of Queensland, St. Lucia, Australia.
Andrews
P R
PR
Nice
E C
EC
D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000378:metabolism; D015704:CD4 Antigens / Q000737:chemistry / Q000378:metabolism*; D007700:Kinetics; D008433:Mathematics; D008969:Molecular Sequence Data; D015717:Peptide T / Q000737:chemistry / Q000378:metabolism*; D011485:Protein Binding
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D015717:Peptide T